BASKING RIDGE, N.J., April 11, 2007 (PRIME NEWSWIRE) -- Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTCBB:MBTG) announces today that it has signed a letter of intent with New Marketlink Pharmaceutical Corp., a Philippine pharmaceutical company for the distribution and marketing of its Resurgex(r) product line for the oncology market.
Under the terms of the Letter of Intent, a distribution agreement will be formalized where Millennium will grant exclusive marketing rights to New Marketlink Pharmaceutical, Corp. to distribute and market its line of Resurgex(r) products for cancer patients in the Philippines. Following the launch in the Philippines distribution is expected to expand to Korea, Malaysia, Singapore, Thailand, Vietnam, Taiwan and Indonesia.
New Marketlink Pharmaceutical Corp. is a member of a multi-million dollar conglomerate based in the Philippines with highly successful operations in fast-moving consumer and pharmaceutical products. "Oncology is one of our core competencies, and Resurgex(r) represents an ideal strategic fit for our company," remarked Amado Tadena, Chairman and CEO of New Marketlink Pharma Corp. "Our plan is to initially launch Resurgex(r) in the Philippines, thereafter, introduce this unique product within the Asia Pacific Region," remarked Oscar J. Aragon, President of New Marketlink Pharma.
"The incidence of cancer is growing in this part of the world and New Marketlink Pharma has recognized the superior attributes of Resurgex(r) to help the growing number of cancer patients in the region," according to Jerry Swon, Sr., President of Millennium Biotechnologies Group, Inc.
Resurgex Select(r) was developed to provide a superior source of high-quality calories as opposed to the corn oil and corn syrup-laden products that are found in the marketplace. As with the previous patent issued for Resurgex(r), this additional patent serves to protect the intellectual property of Millennium's new addition to the Resurgex(r) family of products.
About Millennium Biotechnologies, Inc.: Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, Resurgex(r), Resurgex Plus(r), and Resurgex Select(r), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions.
Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTCBB:MBTG). For more information about Millennium Biotechnologies, please contact Jerry Swon, Chief Executive Officer, at jswon@milbiotech.com or call (908) 604-2500. For more information about the Resurgex line of products visit www.resurgex.com.
This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and Resurgex Plus and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially form those anticipated in such forward-looking statements even if experience or future changes make it clear the any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.